Articles • Interviews • Resources
Articles
COMING SOON
Collapsible text is great for longer section titles and descriptions. It gives people access to all the info they need, while keeping your layout clean. Link your text to anything, or set your text box to expand on click. Write your text here...
Understanding Iboga TA, Screening & Kratom/7-OH
IBOGA TOTAL ALKALOID, KRATOM, 7-OH, WITHDRAWAL RESEARCH, PREPARATION & SAFETY At Bufo Healing Sanctuary, we work with Iboga Total Alkaloid (Iboga TA), a full-spectrum preparation containing naturally occurring alkaloids associated with the iboga plant. Our approach is spiritual, ceremonial, and highly individualized. Bufo Healing Sanctuary is not a hospital, medical clinic, detoxification facility, or physician's office. We do not diagnose medical conditions, prescribe medications, provide medical detoxification, or independently provide medical clearance. Because Iboga TA requires thoughtful screening, we review each potential guest individually and work with qualified consultants when additional medical or pharmacological review is appropriate. Participation is never determined from a website questionnaire alone. WHAT IS IBOGA TOTAL ALKALOID? Iboga contains a complex collection of naturally occurring alkaloids. Ibogaine is one of those alkaloids, but it is not the only one. Iboga Total Alkaloid, commonly called Iboga TA, contains a broader spectrum of the alkaloids extracted from iboga rather than isolated ibogaine hydrochloride (Ibogaine HCl). Bufo Healing Sanctuary works with Iboga TA. We do not provide high-dose Ibogaine HCl flood treatments. Ibogaine and related iboga alkaloids have received increasing scientific attention for their potential relationship to substance dependence, withdrawal, craving, psychological insight, and neuroplasticity. Human observational research has documented promising outcomes involving reductions in opioid withdrawal symptoms and cravings. Researchers are continuing to investigate the neurological and pharmacological mechanisms involved. These findings are encouraging, although individual responses vary and the research does not establish a guaranteed outcome. IBOGA, THE BRAIN & THE NERVOUS SYSTEM Ibogaine has an unusually complex pharmacological profile. Research indicates interactions with several neurotransmitter and receptor systems, including mu and kappa opioid receptors, NMDA and glutamate signaling, serotonin systems, dopamine systems, nicotinic acetylcholine receptors, and sigma receptor systems. Ibogaine is also metabolized into noribogaine, an active metabolite with its own pharmacological properties. Researchers continue to investigate how these multiple mechanisms may contribute to reported changes in withdrawal, craving, mood, reward processing, and substance-use behavior. The term neurological reset is sometimes used to describe the profound changes individuals report following ibogaine experiences. Although this language reflects an emerging area of scientific interest, it should not be interpreted as a literal or universally established resetting of the brain. UNDERSTANDING KRATOM Kratom (Mitragyna speciosa) is a tree native to Southeast Asia. Its leaves contain numerous naturally occurring alkaloids. Two of the most studied are mitragynine and 7-hydroxymitragynine, commonly called 7-OH. Mitragynine and 7-OH interact with the human mu-opioid receptor. Research describes them as partial mu-opioid receptor agonists, although their pharmacology differs considerably from traditional opioids. Regular use can lead to tolerance, physical dependence, and withdrawal in some individuals. PLAIN-LEAF KRATOM AND CONCENTRATED 7-OH ARE NOT THE SAME This distinction has become increasingly important. Traditional kratom leaf contains primarily mitragynine, while naturally occurring 7-hydroxymitragynine is present in much smaller quantities. The modern marketplace now includes concentrated, enriched, and semi-synthetic 7-OH products capable of producing exposures very different from traditional kratom leaf. These products may be sold as tablets, extracts, shots, films, capsules, or other formulations. For screening purposes, simply telling us that you use kratom is not enough information. We need to understand exactly what has been used. KRATOM & 7-OH DEPENDENCE Physical dependence can develop with repeated kratom or concentrated 7-OH exposure. Withdrawal experiences vary considerably depending upon the individual, product, amount, frequency, duration of use, and other substances being taken. Reported withdrawal experiences can include restlessness, muscle and body aches, gastrointestinal discomfort, sweating, chills, difficulty sleeping, anxiety, irritability, low mood, fatigue, and cravings. Concentrated 7-OH products are an especially important consideration because they can produce substantially greater 7-OH exposure than traditional leaf preparations. WHY WE ASK DETAILED QUESTIONS ABOUT KRATOM & 7-OH If you currently use or recently discontinued kratom or 7-OH, please disclose the exact product or brand when known. We also ask whether the product is plain leaf, powder, capsules, extracts, shots, tablets, films, or concentrated 7-OH. Additional information includes the amount used, frequency, length of use, highest recent use, taper history, other substances used concurrently, the date and exact time of your final dose, and any current withdrawal symptoms. Full disclosure helps us understand your individual situation and determine what additional review may be appropriate. Bufo Healing Sanctuary does not prescribe, direct, or medically manage kratom or 7-OH tapers. OUR APPROACH TO KRATOM & 7-OH BEFORE IBOGA TA Some ibogaine programs administer ibogaine relatively close to the final opioid or kratom dose as part of medically managed detoxification protocols. That is not the model used by Bufo Healing Sanctuary. We are not a medical detoxification facility. Our approach is intentionally more conservative. We prefer that a guest has completed their taper and has had meaningful time completely free from kratom or 7-OH before participation. For individuals with recent dependence, withdrawal, concentrated 7-OH use, or other complicating factors, additional consultant or medical review may be required before acceptance. Timing is individualized rather than determined by a single universal number. VITAMIN C & OPIOID WITHDRAWAL RESEARCH Vitamin C, also known as ascorbic acid, has been investigated for its potential role in supporting individuals experiencing opioid withdrawal. Research into high-dose vitamin C and opioid withdrawal has existed for decades, including human clinical observations and published studies examining its relationship to withdrawal severity, physical discomfort, and nervous system responses. One frequently referenced human study was published in 2000 by Evangelou and colleagues. The researchers investigated high-dose oral vitamin C combined with vitamin E in individuals withdrawing from heroin. The study reported reduced withdrawal severity among participants receiving vitamin supplementation compared with the control group. This research helped generate continued interest in vitamin C as a potentially valuable nutritional adjunct during opioid withdrawal. Additional published literature has explored the relationship between vitamin C, pain modulation, opioid signaling, oxidative stress, and physiological responses associated with opioid exposure and withdrawal. Vitamin C is an essential nutrient involved in collagen synthesis, antioxidant activity, immune function, and normal nervous system processes. Its potential relationship to opioid withdrawal has attracted attention because withdrawal involves complex changes in neurological signaling, stress responses, and physical regulation. Researchers have investigated several possible mechanisms, including antioxidant activity, endogenous opioid signaling, pain modulation, and oxidative stress. Although these mechanisms remain under investigation, the published research provides a meaningful foundation for continued scientific exploration. UNDERSTANDING HIGH-DOSE VITAMIN C PROTOCOLS Several high-dose vitamin C approaches have been described in clinical literature, practitioner discussions, and withdrawal-support resources. One commonly referenced approach is the Schauss sodium ascorbate protocol. These approaches generally involve a period of preparation before opioid discontinuation, followed by structured vitamin C supplementation during the withdrawal period. Buffered forms of vitamin C, including sodium ascorbate, have received particular attention because they may be better tolerated gastrointestinally by some individuals than ordinary ascorbic acid. Some protocols describe gradually increasing vitamin C intake before withdrawal and adjusting supplementation according to individual tolerance and symptoms. The published research and clinical observations suggest that vitamin C may have a supportive role in reducing certain withdrawal symptoms for some individuals. However, these protocols are not universally standardized or established as first-line medical treatment. The existing studies are not sufficient to determine a single safe and effective high-dose regimen for all individuals. High-dose vitamin C can cause diarrhea, abdominal discomfort, and other adverse effects. It may also present additional risks for people with kidney disease, a history of kidney stones, iron-overload disorders, or certain metabolic conditions. For these reasons, individuals considering high-dose supplementation should review the approach with an appropriately qualified healthcare professional. VITAMIN C, KRATOM & CONCENTRATED 7-OH Because kratom alkaloids and concentrated 7-hydroxymitragynine interact with opioid receptors, research involving vitamin C and traditional opioid withdrawal has generated interest among individuals seeking supportive approaches when discontinuing these substances. Vitamin C protocols are increasingly discussed in educational and peer-support settings involving kratom and concentrated 7-OH withdrawal. However, the published human research involving vitamin C has primarily focused on traditional opioids, including heroin. The findings cannot automatically be assumed to produce the same results for kratom or concentrated 7-OH dependence. At Bufo Healing Sanctuary, we believe individuals deserve access to educational information about nutritional approaches, published research, and available supportive resources as they prepare for their personal journey. Our intention is to encourage informed preparation, personal responsibility, and greater awareness of the resources available to support the body and nervous system. Bufo Healing Sanctuary may share educational information about vitamin C research and published protocols, but we do not prescribe high-dose supplementation or independently manage withdrawal. Individuals experiencing significant opioid, kratom, or 7-OH withdrawal should seek appropriate medical guidance. Vitamin C is not a substitute for medically indicated withdrawal care. HYDRATION, MAGNESIUM, POTASSIUM & ELECTROLYTE SUPPORT Proper hydration and electrolyte balance are important aspects of physical preparation, particularly for individuals experiencing opioid, kratom, or 7-OH withdrawal. Withdrawal symptoms such as sweating, diarrhea, vomiting, and reduced food or fluid intake can contribute to dehydration and electrolyte imbalances. Electrolytes are minerals that carry electrical charges and support essential physiological functions, including nerve communication, muscle contraction, fluid regulation, and normal cardiac activity. Maintaining appropriate electrolyte levels is particularly important when preparing for an experience involving Iboga TA because ibogaine and noribogaine can influence the electrical activity of the heart. MAGNESIUM Magnesium is an essential mineral involved in hundreds of biochemical processes throughout the body. It contributes to normal nerve signaling, muscle function, energy production, and cardiac electrical stability. Magnesium also participates in processes involving neurotransmitter activity and nervous system regulation. Low magnesium levels can contribute to muscle cramping, weakness, and abnormalities in cardiac electrical activity. Magnesium deficiency may increase susceptibility to certain heart rhythm disturbances, particularly when other electrolyte abnormalities are present. Maintaining an appropriate magnesium level is therefore an important consideration during medical screening for Iboga TA. POTASSIUM Potassium is one of the body's primary electrolytes and plays a central role in maintaining normal heart rhythm, muscle contraction, and nerve communication. Potassium is especially important in cardiac repolarization, the electrical process that allows the heart muscle to prepare for its next contraction. Low potassium levels can increase the risk of abnormal heart rhythms, including potentially dangerous arrhythmias. Because ibogaine and noribogaine can prolong the QT interval, potassium abnormalities are particularly important to identify before exposure. Excess potassium can also be dangerous, particularly in individuals with kidney disease or those taking certain medications. Potassium supplementation should therefore be guided by appropriate medical evaluation rather than assumed to be necessary. SODIUM & HYDRATION Sodium plays an important role in maintaining fluid balance, blood volume, nerve signaling, and muscle function. Individuals experiencing withdrawal may lose fluid and sodium through sweating, vomiting, or diarrhea. Adequate hydration supports normal physiological function, but hydration needs vary according to individual health, activity, medications, and fluid losses. Drinking excessive amounts of plain water without appropriate electrolyte replacement can also create problems, including dilution of blood sodium levels. For this reason, hydration should focus on maintaining appropriate fluid and electrolyte balance rather than simply consuming large quantities of water. Oral rehydration solutions may be useful when fluid and electrolyte losses occur, provided they are appropriate for the individual's medical circumstances. CALCIUM Calcium is essential for muscle contraction, nerve communication, and normal cardiac electrical function. Abnormal calcium levels can influence the QT interval and contribute to changes in cardiac rhythm. For individuals preparing for Iboga TA, calcium is another relevant consideration when reviewing laboratory results and overall electrolyte balance. ELECTROLYTES & IBOGA TA CARDIAC SAFETY Ibogaine and its active metabolite, noribogaine, are associated with QT prolongation and potentially serious ventricular arrhythmias. Electrolyte disturbances, particularly low potassium, low magnesium, or low calcium, can increase cardiac electrical instability. This makes electrolyte evaluation especially important for individuals with recent withdrawal symptoms, dehydration, gastrointestinal illness, poor nutritional intake, or other relevant medical concerns. Appropriate electrolyte levels are an important component of risk assessment, but normal laboratory results do not eliminate the cardiac risks associated with ibogaine. A comprehensive evaluation may include a 12-lead EKG, laboratory testing, medication review, and qualified medical assessment. Some individuals may require additional monitoring or correction of abnormalities before participation can even be considered. NUTRITIONAL PREPARATION & INDIVIDUAL RESPONSIBILITY At Bufo Healing Sanctuary, we recognize the relationship between nourishment, hydration, physical preparation, and overall nervous system awareness. We encourage individuals to pay attention to their nutritional needs, hydration, rest, and general physical well-being during preparation. Foods naturally containing magnesium, potassium, calcium, and other essential nutrients can contribute to a balanced nutritional foundation. Supplementation is not automatically appropriate for everyone. Kidney function, medications, underlying medical conditions, laboratory findings, and individual tolerance can all influence whether additional minerals or electrolytes are needed. High-dose supplementation, especially potassium or magnesium, should not be undertaken without appropriate medical guidance. Our role is to provide education, encourage awareness, and support thoughtful preparation while recognizing that medical evaluation and treatment belong with qualified healthcare professionals. SCREENING BEFORE IBOGA TA Our process begins with getting to know the individual rather than simply looking at laboratory numbers. Potential guests move through several layers of screening. DISCOVERY ZOOM CALL The Discovery Zoom gives us an opportunity to meet face-to-face, discuss why you feel called to the experience, understand your history, and determine whether continuing the screening process feels aligned. INTAKE WAIVER & PERSONAL HISTORY We review relevant information including medical history, medications, supplements, substance use, kratom and 7-OH use, previous psychedelic or sacred medicine experiences, mental and emotional history, current physical concerns, and contraindications. Additional information or consultant review may be requested based upon the individual. EKG & ECG SCREENING Ibogaine is known to affect cardiac electrical conduction, including the QT interval. For this reason, cardiac screening is an important component of our Iboga TA intake process. Bufo Healing Sanctuary currently requests a recent 12-lead EKG or ECG, generally completed within the previous three to six months, containing appropriate cardiac measurements and professional interpretation. Relevant information may include QT and QTc measurements, PR interval, QRS duration, heart rhythm, and physician or qualified clinician interpretation. Depending on the individual and the timing of participation, more recent cardiac evaluation may be necessary. A urine drug screen may also be conducted by Bufo Healing Sanctuary as part of the screening process. A consumer wearable or portable rhythm reading showing only normal sinus rhythm does not necessarily contain the information needed for Iboga screening. Bufo Healing Sanctuary does not independently diagnose cardiac conditions or medically interpret an EKG. When questions arise, additional review may be requested. LABORATORY INFORMATION Depending upon the individual and consultant review, laboratory information may also be requested. This can include information related to electrolytes, potassium, magnesium, calcium, liver function, kidney function, complete blood count, and other laboratory values relevant to the individual's history. The exact information requested may vary because screening is individualized. MEDICATIONS, SUPPLEMENTS & OTHER SUBSTANCES It is extremely important that we receive a complete list of substances being used. This includes prescription medications, over-the-counter medications, psychiatric medications, supplements, herbal preparations, sleep aids, stimulants, kratom, 7-OH, recreational substances, and other sacred medicines. Please include the name, amount, frequency, duration of use, and timing of the most recent dose whenever possible. Do not discontinue a prescribed medication solely because you wish to participate in a retreat. Medication changes and tapering decisions belong between the individual and the appropriately qualified professional overseeing that medication. WHY CARDIAC SCREENING MATTERS One of the most consistently documented physiological concerns associated with ibogaine is QT and QTc prolongation. Ibogaine and noribogaine can influence cardiac repolarization, and published human literature contains reports of significant QT prolongation and ventricular arrhythmias. These effects can be serious and potentially life-threatening. This is one reason we take screening seriously even when someone feels healthy and has no known cardiac history. Screening does not guarantee that an adverse event cannot occur. It is one component of determining whether someone appears appropriate for further consideration. Because serious cardiac complications can occur despite initial screening, an EKG alone does not establish medical safety for ibogaine exposure. NORIBOGAINE The body metabolizes ibogaine primarily into noribogaine. Noribogaine remains present longer than ibogaine itself and is pharmacologically active. Research suggests that noribogaine contributes to some of the longer-lasting pharmacological effects associated with ibogaine. Noribogaine has attracted scientific interest because of its interactions with serotonin transporters, opioid receptors, and other neurological pathways. Researchers continue to investigate its possible relationship to changes in cravings, mood, reward processing, and substance-use behaviors. Human pharmacokinetic literature supports the presence of clinically relevant noribogaine concentrations for days following ibogaine administration. Longer-lasting psychological or behavioral changes should not automatically be interpreted as evidence that substantial concentrations of noribogaine remain circulating for weeks or months. WHAT THE RESEARCH SAYS ABOUT WITHDRAWAL & CRAVING Ibogaine research involving opioid dependence has produced encouraging findings. Small observational studies have reported substantial reductions in opioid withdrawal scores following ibogaine administration. Some participants have also reported reductions in subsequent opioid use and cravings. These findings have contributed to growing scientific interest in ibogaine and its potential applications involving substance dependence. Researchers are investigating how ibogaine and noribogaine interact with neurological pathways associated with opioid dependence, reward processing, and withdrawal. At the same time, the evidence base remains relatively small. Much of the published human research comes from observational studies, open-label research, retrospective reports, and relatively small participant groups rather than large randomized controlled clinical trials. There is currently even less direct clinical research specifically studying Iboga TA for kratom or concentrated 7-OH dependence. For this reason, Bufo Healing Sanctuary does not promise a specific percentage of withdrawal elimination, a guaranteed receptor reset, a particular abstinence rate, or complete elimination of cravings. Every person's physiology, history, dependence, preparation, experience, and integration are different. IBOGA TA VS. IBOGAINE HCL Ibogaine HCl is an isolated form of ibogaine. Iboga Total Alkaloid contains a broader spectrum of alkaloids associated with the iboga plant. There are many experiential and practitioner reports describing qualitative differences between TA and HCl. Some individuals describe full-spectrum preparations as having a different experiential character from isolated ibogaine. However, direct human clinical trials demonstrating that TA is medically superior to Ibogaine HCl for kratom or 7-OH dependence are currently lacking. For that reason, we do not claim that TA has been scientifically proven to be safer, more effective, or more complete than HCl. Both preparations can involve serious medical risks, including potentially life-threatening cardiac complications. Iboga TA is the form of this medicine with which Bufo Healing Sanctuary chooses to work. PREPARATION & INTEGRATION For us, the experience is larger than the medicine itself. Preparation creates the foundation before arrival. Integration creates space to understand and embody what unfolds afterward. Our process can include a Discovery Zoom, intake and screening, preparation and pre-integration, sacred intention, ceremonial support, rest and grace days, nourishing food, nature connection, reflection, and post-experience integration. We recognize that integration does not look the same for everyone. Some people process through conversation and journaling. Others need quiet, movement, nature, swimming, walking, creativity, prayer, or solitude. We honor the individuality of that process. Preparation is not simply about arriving for a ceremony. It is about developing awareness of the body, mind, nervous system, personal history, and the patterns that may have contributed to where someone finds themselves today. Integration is an ongoing process of bringing new awareness into daily life through personal responsibility, conscious choices, self-reflection, and meaningful change. OUR SCOPE Bufo Healing Sanctuary is a sacred sanctuary dedicated to preparation, awareness, spiritual exploration, and integration. We are not physicians and do not represent ourselves as a hospital, medical clinic, addiction-treatment center, or detoxification facility. Our role includes sacred medicine facilitation, spiritual support, preparation, integration, education, screening, and creating an intentional sanctuary environment. When something falls outside our scope, we may seek information or review from qualified consultants and require additional documentation before deciding whether participation is appropriate. Consultant review does not replace necessary medical care, clinical monitoring, or emergency services. Acceptance into a retreat remains individualized. EDUCATIONAL DISCLAIMER The information on this page is provided for educational purposes and describes the screening philosophy and practices of Bufo Healing Sanctuary. It is not medical advice, diagnosis, treatment, detoxification guidance, or a substitute for individualized care from an appropriately qualified healthcare professional. Research involving ibogaine, Iboga Total Alkaloid, kratom, 7-hydroxymitragynine, vitamin C, and related compounds continues to evolve. Scientific findings discussed here should not be interpreted as guarantees of safety or outcome. Bufo Healing Sanctuary does not guarantee that Iboga TA will eliminate withdrawal, addiction, cravings, depression, anxiety, trauma, or any other condition. Our intention is to provide transparent information so that every potential guest can make an informed and sovereign decision about whether this path feels aligned. RESEARCH REFERENCES Evangelou A. and colleagues, 2000. Clinical research examining high-dose vitamin C and vitamin E during heroin withdrawal. https://pubmed.ncbi.nlm.nih.gov/10836211/ Vitamin C, Pain and Opioid Use Disorder, 2020. A review exploring vitamin C, opioid-related mechanisms, and clinical observations. https://pmc.ncbi.nlm.nih.gov/articles/PMC7572147/ Opioids and Vitamin C, 2022. A review discussing vitamin C and its possible relationship to opioid-related physiological processes. https://pmc.ncbi.nlm.nih.gov/articles/PMC9312198/
COMINGS SOON
Collapsible text is great for longer section titles and descriptions. It gives people access to all the info they need, while keeping your layout clean. Link your text to anything, or set your text box to expand on click. Write your text here...
COMING SOON
